



## BACTERIAL DISEASES

BBD-052

### **MYCOPLASMA HYOPNEUMONIAE ELIMINATION IN A FARROW TO FINISH UNIT IN BRITTANY USING AIVLOSIN® WATER SOLUBLE GRANULES (WSG)**

M. Bota<sup>1</sup>, E. Marco<sup>2</sup>, J. Mora<sup>3</sup>.

<sup>1</sup>Hyovet, Plestan, France; <sup>2</sup>Marco Vet Grup, Barcelona, Spain; <sup>3</sup>Eco Animal Health Ltd., Southgate, United Kingdom.

#### **Introduction**

A *Mycoplasma hyopneumoniae* (Mhyo) elimination project was initiated in a unit that broke down when production began. The unit was located in a high-density area in Brittany and was equipped with a HEPA filtration system. The unit started filling up with breeding stock in September 2016. The first signs of pneumonia on the site were detected in the first sows at weaning one month later. Mhyo was later confirmed by serology of their piglets.

#### **Initial Program**

Partial depopulation was undertaken with all weaned animals moved off-site, leaving only breeding inventory on-farm. Two weeks later, sows were medicated with Avlosin® WSG at 8 mg tylvalosin/kg/day for 28 days via liquid feed. They were also injected with Draxxin® (100 mg/ml) at 1ml/40 kg IM at farrowing. Piglets were injected IM with Draxxin® (25mg/ml) 0.3 ml/piglet at birth and at 15-18 days of age at 1ml/10 kg.

A strict biosecurity program was implemented. Mhyo negative replacement gilts were introduced monthly.

#### **Additional measures taken**

Following a review, introduction of replacement gilts was halted for the duration of the medication programme. The Aivlosin® WSG dose was reduced to 5 mg tylvalosin/kg/day but treatment duration was extended by 21 additional days. Sow treatment with Draxxin® was delayed until the final day of the Aivlosin® medication.

Quarantined gilts, later used as sentinels, received the same medication program as the sows. Piglets weaned March 2017 were the first to remain on site.

#### **Results**

After completing the program in March 2017, sentinel gilts were introduced into the herd and tested regularly for Mhyo via PCR (orolaryngeal swabs) and ELISA (serology).

All samples collected over the following nine months were negative.

#### **Discussion and conclusion**

This experience demonstrates that it is possible to achieve Mhyo elimination using Aivlosin® without interrupting the introduction of negative replacements until the final stage.